These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 7964957

  • 1. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [Abstract] [Full Text] [Related]

  • 2. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
    Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W.
    J Clin Oncol; 1998 Mar; 16(3):890-6. PubMed ID: 9508170
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi JJ.
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
    Ludwig H, Cohen AM, Huber H, Nachbaur D, Jungi WF, Senn H, Günczler P, Schüller J, Eckhardt S, Seewann HL.
    Eur J Cancer; 1991 Aug; 27 Suppl 4():S40-5. PubMed ID: 1799476
    [Abstract] [Full Text] [Related]

  • 8. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.
    Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521
    [Abstract] [Full Text] [Related]

  • 9. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
    Bladé J, San Miguel JF, Escudero ML, Fontanillas M, Besalduch J, Gardella S, Arias J, García-Conde J, Carnero M, Marti JM, Rozman C, Estapé J, Montserrat E.
    Leukemia; 1998 Jul 15; 12(7):1144-8. PubMed ID: 9665202
    [Abstract] [Full Text] [Related]

  • 10. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
    Bladé J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcalá A, Brunet S, García-Conde J, Besalduch J, Moro MJ, Fernández-Calvo J, Conde E, Font L, Gardella S, Carnero M, Carbonell F, Martí JM, Hernández-Martín J, Ortega F, Besses C, Ribera JM, Trujillo J, Escudero ML, Rozman C, Estapé J, Montserrat E.
    Hematol J; 2001 Jul 15; 2(4):272-8. PubMed ID: 11920260
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A.
    J Clin Oncol; 1993 Jun 15; 11(6):1165-71. PubMed ID: 8501503
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
    Zervas K, Pouli A, Perifanis V, Papanastasiou K, Chatziyianni M, Mitsouli C, Maniatis A.
    Eur J Haematol; 1996 Aug 15; 57(2):142-8. PubMed ID: 8856091
    [Abstract] [Full Text] [Related]

  • 17. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun HJ, von Broen IM, Fischer JT, Gramatzki M.
    Onkologie; 1990 Dec 15; 13(6):458-60. PubMed ID: 2092283
    [Abstract] [Full Text] [Related]

  • 18. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F.
    J Clin Oncol; 1991 Mar 15; 9(3):444-8. PubMed ID: 1999714
    [Abstract] [Full Text] [Related]

  • 19. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
    Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun HJ, Fett W, Fischer JT, Göbel B.
    Eur J Cancer; 1995 Mar 15; 31A(2):146-51. PubMed ID: 7718318
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
    Dimopoulos MA, Weber D, Delasalle KB, Alexanian R.
    Cancer; 1993 Nov 01; 72(9):2589-92. PubMed ID: 8402480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.